SL Science Holding Ltd

SL Science presents new preclinical data on its γδ T cell glioblastoma therapy at the 85th Annual Meeting of the Japanese Cancer Association, showing the platform targets chemo-resistant MGMT-positive tumor cells. Read the full findings now.

SL Science於第85屆日本癌症學會年會發表最新臨床前數據，顯示其γδT細胞膠質母細胞瘤治療平台能優先鎖定具化療抗性的MGMT陽性腫瘤細胞，為復發性腦癌治療開闢新方向。立即閱讀完整研究內容！

SL Science (Nasdaq: SLBT) rings the Nasdaq bell, marking a first quarter of progress on its γδT cell platform — from an Orphan Drug Designation request to a WCP 2026 presentation and FDA Drug Master File filings.

SL Science (Nasdaq: SLBT) rings the Nasdaq bell, marking a first quarter of progress on its γδT cell platform — from an Orphan Drug Designation request to a WCP 2026 presentation and FDA Drug Master File filings.

SL Science highlights a new FDA Drug Master File (DMF #044612) for GDT cell-derived exosomes, extending its regulatory foundation and addressing blood-brain barrier delivery in glioblastoma.

SL Science宣布GDT細胞衍生外泌體取得新FDA藥物主檔案（DMF #044612），延伸技術平台製造與品質文件基礎，為突破血腦屏障、治療膠質母細胞瘤提供潛在解方。

SL Science leadership and Taipei Medical University co-author a peer-reviewed γδ T cell therapy glioblastoma framework, covering off-the-shelf manufacturing and localized brain delivery. Read the full study now!

L Science 經營層與台北醫學大學共同發表 γδ T細胞治療膠質母細胞瘤同儕審查論文，勾勒嚴謹臨床開發框架，涵蓋異體現成型量產、腦部局部投遞等關鍵技術。

SL Science (Nasdaq: SLBT), together with Taipei Medical University, JY BioMed, and HeXun Biosciences, presented breakthrough gamma delta T cell therapy preclinical data for glioblastoma at WCP2026 Melbourne. Tumor signal dropped to undetectable at the highest dose. Read the full results now.

SL Science（Nasdaq: SLBT）與台北醫學大學、集研生醫及和迅生命科學，於 2026 世界基礎與臨床藥理學大會（WCP2026）墨爾本，發表 γδ T 細胞治療膠質母細胞瘤臨床前突破成果。最高劑量組腫瘤訊號降至無法偵測。立即閱讀完整成果！